Sab Biotherapeutics Stock Revenue Per Share
| SABSW Stock | USD 0.10 0.01 17.65% |
SAB Biotherapeutics fundamentals help investors to digest information that contributes to SAB Biotherapeutics' financial success or failures. It also enables traders to predict the movement of SAB Stock. The fundamental analysis module provides a way to measure SAB Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SAB Biotherapeutics stock.
| Last Reported | Projected for Next Year | ||
| Revenue Per Share | 0.47 | 0.44 |
SAB | Revenue Per Share |
SAB Biotherapeutics Company Revenue Per Share Analysis
SAB Biotherapeutics' Revenue per Share is a ratio of total revenue earned per one share of common stock over a single fiscal year. It is calculated by dividing sales revenue earned over 12 months by the average number of outstanding shares. Revenue used in the calculation of this ratio is typically recorded when cash or cash equivalents are exchanged for services or goods.
Current SAB Biotherapeutics Revenue Per Share | 0.44 |
Most of SAB Biotherapeutics' fundamental indicators, such as Revenue Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SAB Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
SAB Revenue Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for SAB Biotherapeutics is extremely important. It helps to project a fair market value of SAB Stock properly, considering its historical fundamentals such as Revenue Per Share. Since SAB Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of SAB Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of SAB Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
SAB Revenue Per Share Historical Pattern
Today, most investors in SAB Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various SAB Biotherapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of SAB Biotherapeutics revenue per share as a starting point in their analysis.
SAB Biotherapeutics Revenue Per Share |
| Timeline |
Revenue per share does not take into account any of company expenses and is helpful only when comparing relative sale figures within a given industry.
| Competition |
SAB Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
SAB Revenue Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SAB Biotherapeutics' direct or indirect competition against its Revenue Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SAB Biotherapeutics could also be used in its relative valuation, which is a method of valuing SAB Biotherapeutics by comparing valuation metrics of similar companies.SAB Biotherapeutics is currently under evaluation in revenue per share category among its peers.
SAB Fundamentals
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (34.23) % | ||||
| Number Of Shares Shorted | 1.71 K | ||||
| Price To Earning | 0.21 X | ||||
| Revenue | 2.24 M | ||||
| EBITDA | (38.13 M) | ||||
| Net Income | (42.19 M) | ||||
| Total Debt | 5.91 M | ||||
| Book Value Per Share | 4.00 X | ||||
| Cash Flow From Operations | (25.12 M) | ||||
| Earnings Per Share | 0.29 X | ||||
| Number Of Employees | 57 | ||||
| Beta | 0.64 | ||||
| Total Asset | 83.94 M | ||||
| Retained Earnings | (90.06 M) | ||||
| Working Capital | 48.09 M | ||||
| Net Asset | 83.94 M |
About SAB Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SAB Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.